Literature DB >> 26339363

Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status.

Min Ju Kim1, Woo Hee Jung2, Ja Seung Koo2.   

Abstract

The aim of this study is to investigate the expression of sarcosine metabolism related proteins according to androgen receptor (AR) and HER-2 status in estrogen receptor (ER) negative breast cancer and to analyze its clinical implications. Tissue microarray was constructed for a total of 334 cases of ER negative breast cancer. Immunohistochemical stain was conducted for sarcosine metabolism related proteins such as glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX). There were 131 AR positive, 205 AR negative cases and 143 HER-2 positive, 193 HER-2 negative cases. When subdividing into four groups according to AR and HER-2 status, there were 55 AR(+)/HER-2(-) cases, 76 AR(+)/HER-2(+) cases, 67 AR(-)/HER-2(+) cases and 138 AR(-)/HER-2(-) cases. GNMT and PIPOX expression was highest in the AR(+)/HER-2(-) group while expressed lowest in the AR(-)/HER-2(-) group (P<0.001). Stromal PIPOX expression was highest in the AR(-)/HER-2(+) group and lowest in the AR(-)/HER-2(-) group (P=0.010). GNMT and PIPOX expression was higher in the AR positive group compared with those of AR negative group (P=0.001, and P<0.001, respectively), while tumoral and stromal PIPOX expression showed a significant association with HER-2 positivity (P=0.006, and P=0.005, respectively). AR positive group had the highest ratio of low sarcosine type while the AR negative group had the highest ratio of null type (P<0.001). In conclusion, ER negative breast cancer showed different expression of sarcosine metabolism related proteins according to AR and HER-2 status. GNMT and PIPOX expression was high in the AR positive group while tumoral and stromal PIPOX expression was high in the HER-2 positive group.

Entities:  

Keywords:  Androgen receptor; breast cancer; sarcosine

Mesh:

Substances:

Year:  2015        PMID: 26339363      PMCID: PMC4555691     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  14 in total

1.  Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

Authors:  Florian Jentzmik; Carsten Stephan; Michael Lein; Kurt Miller; Beate Kamlage; Bianca Bethan; Glen Kristiansen; Klaus Jung
Journal:  J Urol       Date:  2010-12-18       Impact factor: 7.450

2.  Sarcosine as a potential prostate cancer biomarker and therapeutic target.

Authors:  Caitlin E Baum; Douglas K Price; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-03-26       Impact factor: 4.742

3.  Identification of molecular apocrine breast tumours by microarray analysis.

Authors:  Pierre Farmer; Herve Bonnefoi; Veronique Becette; Michele Tubiana-Hulin; Pierre Fumoleau; Denis Larsimont; Gaetan Macgrogan; Jonas Bergh; David Cameron; Darlene Goldstein; Stephan Duss; Anne-Laure Nicoulaz; Cathrin Brisken; Maryse Fiche; Mauro Delorenzi; Richard Iggo
Journal:  Oncogene       Date:  2005-07-07       Impact factor: 9.867

4.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters.

Authors:  V Kuenen-Boumeester; T H Van der Kwast; C C Claassen; M P Look; G S Liem; J G Klijn; S C Henzen-Logmans
Journal:  Eur J Cancer       Date:  1996-08       Impact factor: 9.162

5.  Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma.

Authors:  Cristina Riva; Emanuele Dainese; Giacomo Caprara; Paolo Cossu Rocca; Giovanni Massarelli; Tibor Tot; Carlo Capella; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

6.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

7.  Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.

Authors:  Guillaume Banneau; Mickaël Guedj; Gaëtan MacGrogan; Isabelle de Mascarel; Valerie Velasco; Renaud Schiappa; Valerie Bonadona; Albert David; Catherine Dugast; Brigitte Gilbert-Dussardier; Olivier Ingster; Pierre Vabres; Frederic Caux; Aurelien de Reynies; Richard Iggo; Nicolas Sevenet; Françoise Bonnet; Michel Longy
Journal:  Breast Cancer Res       Date:  2010-08-16       Impact factor: 6.466

8.  Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer.

Authors:  Kyu Yeoun Won; Gou Young Kim; Youn Wha Kim; Jeong Yoon Song; Sung-Jig Lim
Journal:  Hum Pathol       Date:  2009-09-16       Impact factor: 3.466

9.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

Review 10.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

View more
  5 in total

1.  Alcohol consumption and serum metabolite concentrations in young women.

Authors:  Joanne F Dorgan; Seungyoun Jung; Cher M Dallal; Min Zhan; Christina A Stennett; Yuji Zhang; Richard L Eckert; Linda G Snetselaar; Linda Van Horn
Journal:  Cancer Causes Control       Date:  2019-12-11       Impact factor: 2.506

2.  Sox transcription in sarcosine utilization is controlled by Sigma(54) and SoxR in Bacillus thuringiensis HD73.

Authors:  Qi Peng; Chunxia Liu; Bo Wang; Min Yang; Jianbo Wu; Jie Zhang; Fuping Song
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

3.  Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion.

Authors:  Dillon G Patterson; Justin T Roberts; Valeria M King; Dominika Houserova; Emmaline C Barnhill; Aline Crucello; Caroline J Polska; Lucas W Brantley; Garrett C Kaufman; Michael Nguyen; Megann W Santana; Ian A Schiller; Julius S Spicciani; Anastasia K Zapata; Molly M Miller; Timothy D Sherman; Ruixia Ma; Hongyou Zhao; Ritu Arora; Alexander B Coley; Melody M Zeidan; Ming Tan; Yaguang Xi; Glen M Borchert
Journal:  NPJ Breast Cancer       Date:  2017-07-10

4.  MAT2A Localization and Its Independently Prognostic Relevance in Breast Cancer Patients.

Authors:  Pei-Yi Chu; Hsing-Ju Wu; Shin-Mae Wang; Po-Ming Chen; Feng-Yao Tang; En-Pei Isabel Chiang
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

5.  Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.

Authors:  Zbynek Heger; Miguel Angel Merlos Rodrigo; Petr Michalek; Hana Polanska; Michal Masarik; Vitezslav Vit; Mariana Plevova; Dalibor Pacik; Tomas Eckschlager; Marie Stiborova; Vojtech Adam
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.